211915-84-3

• 常用中文名：3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯
• 常用英文名：3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester
• CAS号：211915-84-3
• 分子式：C₂₇H₂₆N₆O₃
• 分子量：482.534
• 相关类别： 医药中间体 杂环化合物 吡啶类化合物 氰基吡啶
• 发布时间：2018-11-25 05:19:34
• 更新时间：2026-06-30 16:57:56

名称

• 中文名: 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯
• 英文名: ethyl 3-[[2-[(4-cyanoanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
• 中文别名: 达比加群杂质7; 2-(3R)-3-哌啶基-1H-异吲哚-1,3(2H)-二酮/(R)-2-(piperidin-3-yl)isoindoline-1,3-dione; 3-(2-(((4-氰基苯基)氨基)甲基)-1-甲基-N-(吡啶-2-基)-1H-苯并[D]咪唑-5-甲酰胺)丙酸乙酯; 31[[-[-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯; 达比加群杂质3(DABRC-03); 路线1中间体N-3; 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸; 3-(2-(((4-氰基苯基)氨基)甲基)-1-甲基-N-(吡啶-2-基)-1H-苯并[D]咪唑-5-羧酰胺基)丙酸乙酯; 乙基 3-(2-(((4-氰基苯基)胺)甲基)-1-甲基-N-(吡啶-2-基)-1H-苯并[D]咪唑-5-羰氨基)丙酸酯; 达比加群酯中间体2; N-[[2-[[(4-氰基苯)胺]甲基]-1甲基-1H-5-苯并咪唑]羰基]3-氨基苯酰基]N-2-吡啶基- -丙氨酸乙酯; 达比脒; 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基; 达比加群酯中间体5; 达比加群脂杂质7; 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯(达比加群酯); N-[[2-[[(4-氰基苯)胺]甲基]-1甲基-1H-5-苯并咪唑]羰基]3-氨基苯酰基]N-2-吡啶基-B-丙氨酸乙酯; 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]…; 甲磺酸达比加群酯中间体; 达比加群酯中间体N-2; 乙基 3-(2-(((4-氰基苯基)胺)甲基)-1-甲基-N-(吡啶-2-基)-1H-苯并[d]咪唑-5-羰氨基)丙酸酯/Ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido)propanoate; 达比加群酯中间体(DBJQ-D); 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基] (吡啶-2-基)氨基]丙; 甲磺酸达比加群酯杂质I; 3-[[[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-H-苯并咪唑-5-基]羰基]吡啶-2-基氨基]丙酸乙酯; 达比加群中间体DB-6; 3-[[[2-[[(4- 氰基苯基 ) 氨基 ] 甲基 ]-1- 甲基 -1H- 苯并咪唑 -5-基 ] 羰基 ] 吡啶 -2- 基氨基 ] 丙酸乙酯(DG11); ETHYL 3-(2-(((4-CYANOPHENYL) AMINO)METHYL)-1-METHYL-N-(PYRIDINE-2-YL)-1H-BENZO [D]聽聽IMIDAZOLE-5-CBOXAMIDO) PROPANOATE; 达比加群脂杂质P; N-[[2-[[(4-氰基苯)胺]甲基]-1甲基-1H-5-苯并咪唑]羰基]3-氨基苯酰基]N-2-吡啶基-B-丙氨酸乙酯,抗血栓药 达比加群中间体; 达比加群乙酯含氰基类似物; 达比加群中间体3; 甲磺酸达比加群酯中间体,N-[[2-[[(4-氰基苯)胺]甲基]-1甲基- 1H-5-苯并咪唑]羰基]3-氨基苯酰 基]N-2-吡啶基-B-丙氨酸乙酯; 达比加群杂质26; 抗凝血剂; N-[[2-[[(4-氰基苯)胺]甲基]-1甲基-1H-5-苯并咪唑]羰基]3-氨基苯酰基]N-2-吡啶基-b-丙氨酸乙酯; 达比加群杂质I; 3-[2-[[(4-氰基苯基)氨基]甲基]-1-甲基-N-(2-吡啶基)-5-苯并咪唑甲酰氨基]丙酸乙酯; 乙基 3-(2-((4-氰基苯基氨基)甲基)-1-甲基-N-(吡啶-2-基)-1 H-苯并[D]咪唑-5-羰基XAMIDO)丙烷OATE
• 英文别名: Ethyl N-[(2-{[(4-cyanophenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninate; 3-[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionate; Ethyl-3-[[[2-[[(4-cyanophenyl) amino] methyl]-1methyl-1H-benzimidazol-5- yl]carbonyl]pyridine-2-ylamino] propionate; β-Alanine, N-[[2-[[(4-cyanophenyl)amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester; Ethyl-3-[[[2-[[(4-Cyanophenyl) Amino] Methyl]-lmethyl-lH-Benzimidazol-5- Yl] carbonyl] Pyridine-2-Ylamino] Propionate; 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide; N-[[2-[[(4-cyanophenyl)amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester; Ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cbox; Ethyl N-[(2-{[(4-cyanophenyl)amino]Methyl}-1-Methyl-1H-benziMidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran Etexilate Intermediate 3; Dabigatran Ethyl Ester Cyano Analog; ETHYL 3-(2-(((4-CYANOPHENYL) AMINO) METHYL)-1-METHYL-N-(PYRIDINE-2-YL)-1H-BENZO IMIDAZOLE-5-CBOXAMIDO) PROPANOATE; Dabigatran iMpurity I; Ethyl 3-({2-[(4-cyano-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-ylamino)propionate; Dabigatran Intermediate 3; DabigatranEtexilateMesylateinterMediates-5; Dabigatran Etexilate Mesylate Intermediate; 3-({2-[(4-cyano-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-ylamino)propionic acid ethyl ester; route 1 N-3 intermediate; 1-methyl-2-[N-(4-cyanophenyl)aminomethyl]benzimidazole-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide; Pradaxa mesylate intermediates，Ethyl N-[(2-{[(4- cyanophenyl)amino]methyl}-1-methyl- 1H-benzimidazol-5-yl)carbonyl]-N- pyridin-2-yl-beta-alaninate; Ethyl 3-[[[2-[[(4-Cyanophenyl)amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]pyridin-2-ylaMino] propionate; ethyl 3-([2-[(4-cyanophenylamino)methyl]-1-methyl-1H-benzimidazole-5-carbonyl]pyridin-2-ylamino)propionate; 3-({2-[(4-cyano-phenylamino)-methyl]-1-methyl-1H-benzoimidazole-5-carbonyl]pyridin-2-ylamino)propion; 3-[[2-[(4-cyanophenylamino)methyl]-1-methyl-1H-benzimidazole-5-carbonyl]pyridin-2-yl-amino]propionate; Ethyl 3-(2-((4-cyanophenylaMino)Methyl)-1-Methyl-N-(pyridin-2-yl); ethyl N-[(2-{[(4-cyanophenyl)amino]methyl}-1-methyl-1H-benzi; 3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester ISO 9001：2015 REACH; DB-6; Ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-c; 1-methyl-2-<2-methylthio-2-(4-methyl-1-piperazino)vinyl>-quinolinium iodide; Dabigatran Impurity 3 (DABRC-03); Dabigatran Impurity 3 Dabigatran Ethyl Ester Cyano Analog; 3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic; [[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester; 3-[2-[[(4-Cyanophenylamino]methyl]-1-methyl-1h-benzimidazol-5-yl]cbony]pyridin-2-ylamino]propionic acid ethyl ester; Ethyl 3-(2-((4-cyanophenylaMino)Methyl)-1-Methyl-N-(pyridin-2-yl)-1H-benzo[d]iMi; N-[[2-[[(4-CYANOPHENYL)AMINO]METHYL]-1-METHYL-1H-BENZIMIDAZOL-5-YL]carbonyl]-N-2-PYRIDINYL-Β-ALANINE, ETHYL ESTER; 6-benzyloxy-9- ((1S, 3R, 3S) -4-benzyloxy-3-benzyloxymethyl-2-methylcyclopentyl) - N - ((4-methoxyphenyl) diphenylmethyl) -9H-purine-2-amine (N7); β-Alanine, N-[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-, ethyl ester; 3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester(DG11); 3-[[[2-[[(4-Cyanophenylamino)methyl]-1-methyl-1H-benzimidazole-5yl]carbonyl]pyridin-2-ylamino]propanoic acid ethyl ester; Ethyl 3-(2-(((4-cyanophenyl); ethyl 3-[[2-[(4-cyanoanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate (Dabigatran etexilate methanesulfonate); 3-[[[2-[[(4-Cyanophenyl)amino]Methyl]-1-Methyl-1H-benziMidazol-5-yl]carbonyl]pyridin-2-ylaMino]propi; 1-methyl-N-(pyridin-2-yl); Dabigatran Etexilate Mesylate impurity I; Deacetamidine Cyano Dabigatran Ethyl Ester; Ethyl 3-(2-(((4-Cyanophenyl) Amino) Methyl)-1-Methyl n-(Pyridine-2-yl)-1H-Benzo [d] Imidazole-5 Cboxamido)Propanoate; Ethyl 3-(2-((4-cyanophenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-cboxamido; Desethyl Dabigatran Etexilate Impurity W; ethyl 3-(2-((4-cyanophenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate; Ethyl 3-[[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propanoate; 1H-benzo[d]imidazole-5-cboxamido); 3-([{2-[(4-Cyanophenyl) amino] methyl-1-methyl -1H-benzimidazol-5-yl} carbonyl] pyridin-2-ylamino) propionic acid ethyl ester (DG-4)- new process; 3-([{2-[(4-Cyanophenyl) amino] methyl-1-methyl -1H-benzimidazol-5-yl} carbonyl] pyridin-2-ylamino) propionic acid ethyl ester (DG-4); N-[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-5-benzimidazole]carbonyl]-3-aminobenzoyl]-N-2-pyridyl-β-alanineethylester; 2,4-Dichlorobenzyl Alcohol Impurity 3 (2,4-Dichlorobenzyl Alcohol Impurity C); Ethyl 3-(2-((4-cyanophenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]; ethyl 3-[[2-[(4-cyanoanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate (Dabigatran etexilate; 3-[[[2-[[(4-CYANOPHENYL) AMINO]METHYL] 1-METHYL-1H-BENZIMIDAZOL-5-YL) carbonyl] PYRIDIN-2-YLAMI NO] PROPIONIC ACID; Ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-6-cboxamido) propanoate; Ethyl N-[(2-{[(4-cyanophenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-β-alaninate; Ethyl 3-[[2-[(4-Cyanoanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-(2-pyridyl)amino]propanoate; 3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl esterChemicalBook; ethyl N-[(2-{[(4-cyanophenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Ethyl 3-(2-(((4-cyanophenyl) amino) methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole -5-cboxamido) propanoate oxalate

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 756.4±60.0 °C at 760 mmHg
• 分子式: C₂₇H₂₆N₆O₃
• 分子量: 482.534
• 闪点: 411.2±32.9 °C
• 精确质量: 482.206635
• PSA: 113.14000
• LogP: 2.85
• 外观性状: 白色到灰白色 固体
• 蒸汽压: 0.0±2.5 mmHg at 25°C
• 折射率: 1.640
• 储存条件: 室温

上下游产品

上游产品  7
42288-26-6 212322-56-0 41263-74-5 82357-48-0
429659-01-8 873-74-5 96-99-1
下游产品  2
872728-81-9 211915-06-9